Here’s what you should know:
1. Dr. McCole is studying how the loss of the intestinal epithelial barrier in the intestine is related to inflammatory bowel disease.
2. Many IBD, celiac disease and type 1 diabetes patients have reduced T-cell protein tyrosine phosphatase activity, which compromises their intestinal epithelial barrier’s function.
3. NIH awarded Dr. McCole the grant specifically to identify how reduced TCPTP activity contributes to barrier defects.
4. In a release, he said, “When TCPTP activity is compromised, errors occur in remodeling cell junctions — the structures that regulate barrier function. The goal of the study is to discover the mechanisms by which loss of TCPTP activity in patients contributes to intestinal barrier defects in IBD. In addition, we hope to identify if strategies to inhibit JAK signaling may prove particularly effective in patients with TCPTP genetic mutations.”
More articles on gastroenterology:
Stock market week-in-review for 5 large GI companies — Aug. 7-11
GI leader to know: Dr. Ross Meidinger of Sanford Health
GI center to know: Mountain West Endoscopy
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
